Elan Announces Restructuring of Tysabri Collaboration with Biogen Idec
Migrate From The Current 50:50
Business Collaboration To A New Structure
Upfront Payment Of $3.25 Billion
Plus Double Digit Tiered Royalty For Complete Asset
Tax Efficient Transaction
Simplified Structure Enables
Improved Alignment Of Therapy To...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals | Tysabri